专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2015028469A3 MARKER FOR STATIN TREATMENT STRATIFICATION IN HEART FAILURE 审中-公开
标题翻译：心脏病治疗分层标志物在心力衰竭中的应用
公开(公告)号：WO2015028469A3
公开(公告)日：2015-05-07
申请号：PCT/EP2014068090
申请日：2014-08-26
申请人： ROCHE DIAGNOSTICS GMBH , HOFFMANN LA ROCHE , BLOCK DIRK , BRUNNER HANSPETER , DIETERLE THOMAS , WIENHUES-THELEN URSULA-HENRIKE , ZAUGG CHRISTIAN , ZIEGLER ANDRE
发明人： BLOCK DIRK , BRUNNER HANSPETER , DIETERLE THOMAS , WIENHUES-THELEN URSULA-HENRIKE , ZAUGG CHRISTIAN , ZIEGLER ANDRE
IPC分类号： G01N33/68 , A61K31/22
CPC分类号： G01N33/6893 , A61K31/40 , G01N33/62 , G01N33/6869 , G01N33/6872 , G01N2333/47 , G01N2333/475 , G01N2333/495 , G01N2333/5412 , G01N2800/325 , G01N2800/52
摘要： The present invention is directed to a method of identifying a patient having heart failure as likely to respond to a therapy comprising a statin. The method is based on measuring the level of at least one marker selected from GDF-15 (Growth Differentiation Factor 15), Urea, SHBG (Sex Hormone-Binding Globulin), Uric acid, PLGF (Placental Growth Factor), IL-6 (Interleukin-6), Transferrin, a cardiac Troponin, sFlt-1 (Soluble fms-like tyrosine kinase-1), Prealbumin, Ferritin, Osteopontin, sST2 (soluble ST2), and hsCRP (high sensitivity C-reactive protein) in a sample from a patient. Further envisaged is a method of predicting the risk of a patient to suffer from death or hospitalization, wherein said patient has heart failure and undergoes a therapy comprising a statin. The method is also based on the measurement of the level of at least one of the aforementioned markers.
摘要翻译：本发明涉及鉴定可能对含有他汀类药物的疗法有反应的心力衰竭患者的方法。该方法基于测量选自GDF-15（生长分化因子15），尿素，SHBG（性激素结合球蛋白），尿酸，PLGF（胎盘生长因子），IL-6（白细胞介素-6），转铁蛋白，心脏肌钙蛋白，sFlt-1（可溶性fms样酪氨酸激酶-1），前白蛋白，铁蛋白，骨桥蛋白，sST2（可溶性ST2）和hsCRP（高敏C反应蛋白）来自患者。进一步设想的是预测患者死亡或住院风险的方法，其中所述患者患有心力衰竭并且经历包含他汀的治疗。该方法也基于至少一个上述标记的水平的测量。

2. 发明申请

WO2015028469A2 MARKER FOR STATIN TREATMENT STRATIFICATION IN HEART FAILURE 审中-公开
标题翻译：心脏失败症状治疗的标记标记
公开(公告)号：WO2015028469A2
公开(公告)日：2015-03-05
申请号：PCT/EP2014/068090
申请日：2014-08-26
申请人： ROCHE DIAGNOSTICS GMBH , F. HOFFMANN-LA ROCHE AG , BLOCK, Dirk , BRUNNER, Hanspeter , DIETERLE, Thomas , WIENHUES-THELEN, Ursula-Henrike , ZAUGG, Christian , ZIEGLER, Andre
发明人： BLOCK, Dirk , BRUNNER, Hanspeter , DIETERLE, Thomas , WIENHUES-THELEN, Ursula-Henrike , ZAUGG, Christian , ZIEGLER, Andre
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , A61K31/40 , G01N33/62 , G01N33/6869 , G01N33/6872 , G01N2333/47 , G01N2333/475 , G01N2333/495 , G01N2333/5412 , G01N2800/325 , G01N2800/52
摘要： The present invention is directed to a method of identifying a patient having heart failure as likely to respond to a therapy comprising a statin. The method is based on measuring the level of at least one marker selected from GDF-15 (Growth Differentiation Factor 15), Urea, SHBG (Sex Hormone-Binding Globulin), Uric acid, PLGF (Placental Growth Factor), IL-6 (Interleukin-6), Transferrin, a cardiac Troponin, sFlt-1 (Soluble fms-like tyrosine kinase-1), Prealbumin, Ferritin, Osteopontin, sST2 (soluble ST2), and hsCRP (high sensitivity C-reactive protein) in a sample from a patient. Further envisaged is a method of predicting the risk of a patient to suffer from death or hospitalization, wherein said patient has heart failure and undergoes a therapy comprising a statin. The method is also based on the measurement of the level of at least one of the aforementioned markers.
摘要翻译：本发明涉及鉴定患有心力衰竭的患者可能对包含他汀类药物的疗法有反应的方法。该方法基于测量选自GDF-15（生长分化因子15），尿素，SHBG（性激素结合球蛋白），尿酸，PLGF（胎盘生长因子），IL-6（白细胞介素-6），转铁蛋白，心肌肌钙蛋白，sFlt-1（可溶性fms样酪氨酸激酶-1），前白蛋白，铁蛋白，骨桥蛋白，sST2（可溶性ST2）和hsCRP（高灵敏度C反应蛋白）从病人。进一步设想的是预测患者遭受死亡或住院的风险的方法，其中所述患者具有心力衰竭并经历包含他汀类药物的治疗。该方法还基于至少一种上述标记的水平的测量。

3. 发明申请

WO2014086833A1 BIOMARKERS IN THE SELECTION OF THERAPY OF HEART FAILURE 审中-公开
标题翻译：生物标志物选择心脏失败的治疗方法
公开(公告)号：WO2014086833A1
公开(公告)日：2014-06-12
申请号：PCT/EP2013/075491
申请日：2013-12-04
申请人： ROCHE DIAGNOSTICS GMBH , F. HOFFMANN-LA ROCHE AG , ZAUGG, Christian , BLOCK, Dirk , WIENHUES-THELEN, Ursula-Henrike , BRUNNER, Hans-Peter , KRAUSE, Friedemann , MODEL, Fabian , ROLNY, Vincent
发明人： ZAUGG, Christian , BLOCK, Dirk , WIENHUES-THELEN, Ursula-Henrike , BRUNNER, Hans-Peter , KRAUSE, Friedemann , MODEL, Fabian , ROLNY, Vincent
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , G01N2333/4745 , G01N2333/475 , G01N2333/705 , G01N2800/325 , G01N2800/52 , G01N2800/60
摘要： The present invention relates to a method for identifying a subject being eligible to the administration of at least one medicament selected from the group consisting of a beta blocker, an aldosterone antagonist, a diuretic, and an inhibitor of the renin-angiotensin system. The method is based on the determination of the amount of at least one biomarker selected from the group consisting of GDF-15 (Growth Differentiation Factor 15), endostatin, mimecan, IGFBP7 (IGF binding protein 7), a cardiac Troponin, a BNP-type peptide, uric acid, Gal3 (Galectin-3), osteopontin, sST2 (soluble ST2), PlGF, sFlt-1, PlNP, Cystatin C, Prealbumin, and Transferrin in a sample from a subject suffering from heart failure. Further, the method comprises the step of comparing the, thus, determined amount with a reference amount. Further envisaged by the present invention are kits and devices adapted to carry out the method of the present invention. The present invention also relates to a system for identifying a subject being eligible to the administration of at least one medicament as disclosed herein and to reagents and kits used in performing the methods as disclosed herein.
摘要翻译：本发明涉及一种用于鉴定有资格给予选自β-阻滞剂，醛固酮拮抗剂，利尿剂和肾素 - 血管紧张素系统抑制剂的至少一种药物的受试者的方法。该方法基于选自GDF-15（生长分化因子15），内皮抑素，mimecan，IGFBP7（IGF结合蛋白7），心肌肌钙蛋白，BNP-15的至少一种生物标志物的量的测定。来自患有心力衰竭的受试者的样品中的类型肽，尿酸，Gal3（Galectin-3），骨桥蛋白，sST2（可溶性ST2），PlGF，sFlt-1，PlNP，半胱氨酸蛋白酶抑制剂C，前白蛋白和转铁蛋白。此外，该方法包括将所确定的量与参考量进行比较的步骤。本发明进一步设想的是适用于实施本发明方法的试剂盒和装置。本发明还涉及用于鉴定合适的给予本文公开的至少一种药物的受试者的系统以及用于执行本文所公开的方法的试剂和试剂盒。

4. 发明申请

WO2014072471A1 NTPROBNP AND CTNT BASED THERAPY GUIDANCE IN HEART FAILURE 审中-公开
标题翻译： NTPROBNP和CTNT基于心脏失败的治疗指导
公开(公告)号：WO2014072471A1
公开(公告)日：2014-05-15
申请号：PCT/EP2013/073399
申请日：2013-11-08
申请人： ROCHE DIAGNOSTICS GMBH , F. HOFFMANN-LA ROCHE AG , BLOCK, Dirk , BRAZ, Julian , BRUNNER, Hans-Peter , CREEDEN, James , LOYDA, Hans-Jürgen , WIENHUES-THELEN, Ursula-Henrike , ZAUGG, Christian
发明人： BLOCK, Dirk , BRAZ, Julian , BRUNNER, Hans-Peter , CREEDEN, James , LOYDA, Hans-Jürgen , WIENHUES-THELEN, Ursula-Henrike , ZAUGG, Christian
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , G01N2800/325
摘要： The present invention relates to a method for guiding heart failure treatment in a subject suffering from heart failure. The method is based on the determination of the amount of a BNP-type peptide and a cardiac troponin in a sample from said subject. Further envisaged by the present invention are kits and devices adapted to carry out the present invention. The present invention also relates to a system for guiding heart failure treatment in a subject suffering from heart failure as disclosed herein and to reagents and kits used in performing the methods disclosed herein.
摘要翻译：本发明涉及一种在患有心力衰竭的受试者中引导心力衰竭治疗的方法。该方法基于来自所述受试者的样品中BNP型肽和心肌肌钙蛋白的量的测定。本发明进一步设想的是适用于实施本发明的试剂盒和装置。本发明还涉及用于指导本文公开的患有心力衰竭的受试者的心力衰竭治疗的系统以及用于执行本文公开的方法的试剂和试剂盒。

5. 发明申请

WO2009127251A1 COMBINATIONS COMPRISING A RENIN INHIBITOR 审中-公开
标题翻译：包含RENIN抑制剂的组合
公开(公告)号：WO2009127251A1
公开(公告)日：2009-10-22
申请号：PCT/EP2008/054586
申请日：2008-04-16
申请人： NOVARTIS AG , SCHUMACHER, Christoph , ZAUGG, Christian , BALTATU, Ovidiu
发明人： SCHUMACHER, Christoph , ZAUGG, Christian , BALTATU, Ovidiu
IPC分类号： A61K31/538 , A61K45/06 , A61P9/12 , A61P3/10 , A61P3/06
CPC分类号： A61K45/06 , A61K31/538 , A61K2300/00
摘要： The invention relates to drug combinations comprising the renin inhibitor of formula (I) or a pharmaceutically acceptable salt thereof with specific cardiovascular treatment agents of complementary pharmacological mechanism to generate a synergistic therapeutic effect.
摘要翻译：本发明涉及包含式（I）的肾素抑制剂或其药学上可接受的盐与具有互补的药理学机制的特定心血管治疗剂的药物组合，以产生协同治疗效果。

6. 发明申请

WO2008077916A1 PHARMACEUTICAL COMPOSITION USING ALISKIREN AND AVOSENTAN 审中-公开
标题翻译：使用阿利昔宁和阿维菌素的药物组合物
公开(公告)号：WO2008077916A1
公开(公告)日：2008-07-03
申请号：PCT/EP2007/064404
申请日：2007-12-21
申请人： SPEEDEL PHARMA AG , SCHUMACHER, Christoph , HUXLEY, Alice , ZAUGG, Christian , BALTATU, Ovidiu
发明人： SCHUMACHER, Christoph , HUXLEY, Alice , ZAUGG, Christian , BALTATU, Ovidiu
IPC分类号： A61K31/165 , A61K31/506 , A61P13/12 , A61P9/08
CPC分类号： A61K31/165 , A61K31/506
摘要： The present invention relates to a pharmaceutical composition and method of achieving a therapeutic effect including, but not limited to, the treatment of hypertension, kidney or heart disease in an animal, preferably a mammal including a human subject, using (i) SPP100/aliskiren or a pharmaceutically acceptable salt thereof in combination with (ii) SPP301/avosentan or a pharmaceutically acceptable salt thereof and (iii) a pharmaceutically acceptable carrier.
摘要翻译：本发明涉及使用（i）SPP100 /阿利吉仑来实现治疗效果的药物组合物和方法，所述药物组合物和方法包括但不限于在动物，优选包括人受试者的哺乳动物中治疗高血压，肾脏或心脏病或其药学上可接受的盐与（ii）SPP301 /阿泊生坦或其药学上可接受的盐组合，和（iii）药学上可接受的载体。

7. 发明申请

WO2005023241A1 THE USE OF FUMARIC ACID DERIVATIVES FOR TREATING CARDIAC INSUFFICIENCY, AND ASTHMA 审中-公开
标题翻译：用于治疗心脏缺血症的乳酸衍生物的使用和ASTHMA
公开(公告)号：WO2005023241A1
公开(公告)日：2005-03-17
申请号：PCT/EP2004/009835
申请日：2004-09-03
申请人： FUMAPHARM AG , JOSHI, Rajendra, Kumar , STREBEL, Hans-Peter , ZAUGG, Christian , TAMM, Michael
发明人： JOSHI, Rajendra, Kumar , STREBEL, Hans-Peter , ZAUGG, Christian , TAMM, Michael
IPC分类号： A61K31/231
CPC分类号： A61K31/225 , A61K31/197 , A61K31/231 , A61K31/573 , A61K2300/00
摘要： According to a first aspect the invention relates to the use of fumaric acid derivatives selected from the group consisting of dialkyl fumarates, monoalkyl hydrogen fumarates, fumaric acid monoalkyl ester salts, fumaric acid monoamides, monoamido fumaric acid salts, fumaric acid diamides, monoalkyl monoamido fumarates, carbocyclic and oxacarbocyclic oligomers of these compounds and mixtures thereof for preparing a drug for the treatment or prevention of cardiac insufficiency, in particular left ventricular insufficiency, myocardial infarction and angina pectoris. According to a second aspect the invention relates to the use of fumaric acid derivatives, selected from the group consisting of dialkyl fumarates, monoalkyl hydrogen fumarates, fumaric acid monoaklyl ester salts, fumaric acid monoamido fumaric acid salts, fumaric acid diamides, monoalkyl monoamido fumarates, carbocyclic and oxacarbocyclic oligomers of these compounds and mixtures thereof for preparing a drug for the treatment of asthma and chronic obstructive pulmonary diseases, especially asthma caused by allergies, infections, analgesics, job conditions or physical effort, mixed forms of asthma, or asthma cardiale.
摘要翻译：根据第一方面，本发明涉及富马酸衍生物的用途，所述富马酸衍生物选自富马酸二烷基酯，富马酸单烷基酯，富马酸单烷基酯盐，富马酸单酰胺，单酰氨基富马酸盐，富马酸二酰胺，单烷基单酰氨基富马酸盐，这些化合物的碳环和氧杂环低聚物及其混合物，用于制备治疗或预防心功能不全，特别是左心室功能不全，心肌梗塞和心绞痛的药物。根据第二方面，本发明涉及富马酸衍生物的用途，所述富马酸衍生物选自富马酸二烷基酯，富马酸单烷基酯，富马酸单烯基酯盐，富马酸单酰氨基富马酸盐，富马酸二酰胺，单烷基单酰氨基富马酸盐，这些化合物的碳环和恶唑环低聚物及其混合物用于制备用于治疗哮喘和慢性阻塞性肺疾病的药物，特别是由过敏，感染，止痛剂，作业条件或身体力量引起的哮喘，混合形式的哮喘或哮喘心脏病。

8. 发明申请

WO2014072500A1 TNT BASED DIAGNOSIS OF PAROXYSMAL ATRIAL FIBRILLATION 审中-公开
标题翻译：基于TNT的PAROXYSMAL ATRIAL FIBRILLATION的诊断
公开(公告)号：WO2014072500A1
公开(公告)日：2014-05-15
申请号：PCT/EP2013/073476
申请日：2013-11-11
申请人： ROCHE DIAGNOSTICS GMBH , F. HOFFMANN-LA ROCHE AG , BLOCK, Dirk , LATINI, Roberto , MASSON, Serge , WIENHUES-THELEN, Ursula-Henrike , ZAUGG, Christian , ZIEGLER, Andre
发明人： BLOCK, Dirk , LATINI, Roberto , MASSON, Serge , WIENHUES-THELEN, Ursula-Henrike , ZAUGG, Christian , ZIEGLER, Andre
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , G01N33/6869 , G01N33/6887 , G01N2333/4712 , G01N2333/4737 , G01N2333/4745 , G01N2333/5412 , G01N2333/58 , G01N2800/326 , G01N2800/52
摘要： The present invention relates to a method for diagnosing a recent paroxysmal atrial fibrillation. The method is based on the determination of the at least one marker selected from the group consisting of a cardiac Troponin, NT-proBNP (N-terminal prohormone of brain natriuretic peptide), hsCRP, IL-6 (Interleukin-6) and IGFBP7 (Insulin like growth factor binding protein 7) in a sample from the subject, and on the comparison of the, thus, determined amount(s) with a reference amount (reference amounts). Further, the present invention relates to a method for identifying a subject being susceptible to anticoagulation therapy. Further envisaged are systems, reagents and kits used in performing the methods disclosed herein.
摘要翻译：本发明涉及一种诊断近期阵发性房颤的方法。该方法基于选自心肌肌钙蛋白，NT-proBNP（脑钠尿肽的N-末端激素原），hsCRP，IL-6（白细胞介素-6）和IGFBP7（来自受试者的样品中的胰岛素样生长因子结合蛋白7）以及由此确定的量与参考量（参考量）的比较。此外，本发明涉及用于鉴定易于抗凝治疗的受试者的方法。进一步设想的是用于执行本文公开的方法的系统，试剂和试剂盒。

9. 发明申请

WO2014040759A1 IDENTIFICATION OF PATIENTS WITH ABNORMAL FRACTIONAL SHORTENING 审中-公开
标题翻译：鉴别患有异常分娩的患者
公开(公告)号：WO2014040759A1
公开(公告)日：2014-03-20
申请号：PCT/EP2013/056706
申请日：2013-03-28
申请人： ROCHE DIAGNOSTICS GMBH , F. HOFFMANN-LA ROCHE AG , BLOCK, Dirk , MASSON, Serge , WIENHUES-THELEN, Ursula-Henrike , ZAUGG, Christian , LATINI, Roberto
发明人： BLOCK, Dirk , MASSON, Serge , WIENHUES-THELEN, Ursula-Henrike , ZAUGG, Christian , LATINI, Roberto
IPC分类号： G01N33/68
CPC分类号： G01N33/6887 , A61B5/055 , A61B8/0883 , G01N33/82 , G01N2333/4703 , G01N2333/4706 , G01N2333/4712 , G01N2333/50 , G01N2333/78 , G01N2800/32 , G01N2800/329 , G01N2800/50
摘要： The present invention relates to a method for assessing whether a subject shall be subjected to an imaging based diagnostic assessment. The method is based on the determination of the amount(s) of a cardiac Troponin and/or Fibroblast Growth Factor 23 (FGF-23) in a sample from the subject, and on the comparison of the, thus, determined amount(s) with a reference amount (reference amounts). The present invention also relates to a system for performing an assessment whether a subject shall be subjected to an imaging based diagnostic assessment and to reagents and kits used in performing the methods disclosed herein. Moreover, the present invention is directed to a method for predicting the risk of mortality and/or of a cardiovascular event. Also encompassed is a method for diagnosing an early stage of LVH in a subject having a preserved left ventricular ejection.
摘要翻译：本发明涉及一种用于评估受试者是否应进行基于成像的诊断评估的方法。该方法基于来自受试者的样品中心肌肌钙蛋白和/或成纤维细胞生长因子23（FGF-23）的量的测定，以及因此确定的量（s）具有参考量（参考量）。本发明还涉及一种用于执行评估受试者是否应进行基于成像的诊断评估的系统以及用于执行本文所公开的方法的试剂和试剂盒。此外，本发明涉及一种用于预测死亡风险和/或心血管事件风险的方法。还包括用于诊断具有保留的左心室射血的受试者的LVH的早期阶段的方法。

10. 发明申请

WO2013017690A3 TROPONIN BASED RULE IN AND RULE OUT ALGORITHM OF MYOCARDIAL INFARCTION 审中-公开
标题翻译：基于肌钙蛋白基的规则和排除心肌梗死的算法
公开(公告)号：WO2013017690A3
公开(公告)日：2013-03-28
申请号：PCT/EP2012065266
申请日：2012-08-03
申请人： ROCHE DIAGNOSTICS GMBH , HOFFMANN LA ROCHE , JARAUSCH JOCHEN , MENASSANCH-VOLKER SYLVIE , MUELLER CHRISTIAN , REICHLIN TOBIAS , VERHAGEN-KAMERBEEK WILMA , WEISER SILVIA , ZAUGG CHRISTIAN
发明人： JARAUSCH JOCHEN , MENASSANCH-VOLKER SYLVIE , MUELLER CHRISTIAN , REICHLIN TOBIAS , VERHAGEN-KAMERBEEK WILMA , WEISER SILVIA , ZAUGG CHRISTIAN
IPC分类号： G01N33/68
CPC分类号： G01N33/6887 , G01N2333/4701 , G01N2800/324
摘要： The present invention relates to a method for diagnosing myocardial infarction in a subject presenting with chest pain. The method is based on the determination the amount of a cardiac Troponinin a first sample from the subject obtained at presentation to a physician, and in a second sample obtained within one hour after the first sample. Moreover, the present invention envisages a method for ruling in myocardial infarction and a method for ruling out myocardial infarction. The said methods are also based on the determination the amount of a cardiac Troponinin a first sample from the subject obtained at presentation to a physician, and in a second sample obtained within one hour after the first sample. The present invention also relates to a system for performing a diagnosis, rule in, or rule of myocardial infarction as disclosed herein and to reagents and kits used in performing the methods disclosed herein.
摘要翻译：本发明涉及用于诊断呈现胸痛的受试者中的心肌梗塞的方法。该方法基于确定在呈现给医师时获得的来自受试者的第一样品的心肌肌钙蛋白的量以及在第一样品之后1小时内获得的第二样品中的量。此外，本发明设想了一种治疗心肌梗塞的方法和一种排除心肌梗塞的方法。所述方法还基于确定在呈现给医师时获得的来自受试者的第一样品的心脏肌钙蛋白的量以及在第一样品之后1小时内获得的第二样品中的量。本发明还涉及用于执行如本文所公开的心肌梗塞的诊断，规则或规则的系统以及用于执行本文公开的方法的试剂和试剂盒。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式